A novel mutation of ALK2, L196P, found in the most benign case of fibrodysplasia ossificans progressiva activates BMP-specific intracellular signaling equivalent to a typical mutation, R206H

作者：Ohte Satoshi; Shin Masashi; Sasanuma Hiroki; Yoneyama Katsumi; Akita Masumi; Ikebuchi Kenji; Jimi Eijiro; Maruki Yuichi; Matsuoka Masaru; Namba Akira; Tomoda Hiroshi; Okazaki Yasushi; Ohtake Akira; Oda Hiromi; Owan Ichiro; Yoda Tetsuya; Furuya Hirokazu; Kamizono Jyunji; Kitoh Hiroshi; Nakashima Yasuharu; Susami Takafumi; Haga Nobuhiko; Komori Tetsuo; Katagiri Takenobu^*

来源：Biochemical and Biophysical Research Communications, 2011, 407(1): 213-218.

DOI：10.1016/j.bbrc.2011.03.001

• FOP
• ALK2
• BMP
• Smad
• Muscle
• Signaling

Fibrodysplasia ossificans progressiva (FOP) is a rare autosomal dominant congenital disorder characterized by progressive heterotopic ossification in muscle tissues. Constitutively activated mutants of a bone morphogenetic protein (BMP) receptor, ALK2, have been identified in patients with FOP. Recently, a novel ALK2 mutation, L196P, was found in the most benign case of FOP reported thus far. In the present study, we examined the biological activities of ALK2(L196P) in vitro. Over-expression of ALK2(L196P) induced BMP-specific activities, including the suppression of myogenesis, the induction of alkaline phosphatase activity, increased BMP-specific luciferase reporter activity, and increased phosphorylation of Smad1/5 but not Erk1/2 or p38. The activities of ALK2(L196P) were higher than those of ALK2(G356D), another mutant ALK2 allele found in patients with FOP and were equivalent to those of ALK2(R206H), a typical mutation found in patients with FOP. ALK2(L196P) was equally or more resistant to inhibitors in comparison to ALK2(R206H). These findings suggest that ALK2(L196P) is an activated BMP receptor equivalent to ALK2(R206H) and that ALK2(L196P) activity may be suppressed in vivo by a novel molecular mechanism in patients with this mutation.

• 出版日期2011-4-1